Glucagon-like peptide-1 agonists have exploded in use and popularity to treat obesity in nondiabetic patients since the approval of semaglutide injection (Wegovy, Novo Nordisk) in 2021. Although more than 90% of patients adhered to GLP-1 agonists through the end of clinical trials, new data suggest that real-world adherence rates are much lower. “Limited literature describes the impact of the BCID2 panel on clinical outcomes in patients with organisms not covered by typical